INDEX 03 / SAFETY / REPORTED ADVERSE EFFECTS
CJC-1295 Side Effects in the Research Literature
What the published Phase 1 studies, the terminated Phase 2 trial, and the observational record have reported as adverse effects of CJC-1295 — short-term, medium-term, and the long-term safety gap.
Reported adverse effects
CJC-1295 side effects as reported in the published clinical record and the observational research literature cluster into a small, consistent set. Most-reported short-term effects: facial flushing, mild headache, injection-site redness, transient water retention, occasional numbness or tingling, and occasional dizziness [3][15]. These are the standard short-term adverse effects associated with GH-axis stimulation broadly and are consistent across the published Phase 1 record [3][4].
The Teichman 2006 Phase 1 ascending-dose study reported no serious adverse reactions at the tested doses in healthy adults [3]. The Ionescu 2006 continuous-stimulation study likewise reported standard short-term effects without serious adverse events at 60 or 90 µg/kg [4]. The principal serious-event record on CJC-1295 is the 2006 fatal myocardial infarction in the terminated Phase 2 lipodystrophy trial (NCT00267527), discussed in its own section below [5].
More serious concerns flagged in the literature
Sustained elevation of growth hormone and IGF-1 — the precise pharmacological signature of CJC-1295-DAC — raises specific theoretical concerns drawn from the broader endocrinology of GH excess.
A 2024 review of GH / IGF-1 / insulin interplay summarizes the mechanism: chronic GH and IGF-1 elevation suppresses the antilipolytic action of insulin, drives lipotoxicity, and promotes hepatic and peripheral insulin resistance with compensatory hyperinsulinemia [15]. The clinical model for chronic GH/IGF-1 elevation is acromegaly, where the metabolic disturbance is well documented [15].
The principal serious-event record on CJC-1295 itself is the 2006 fatal myocardial infarction in a Phase 2 trial participant in Argentina (NCT00267527), which halted industry development [5][9]. The site investigator's attributed cause was asymptomatic coronary artery disease with plaque rupture, judged most likely unrelated to the peptide; the sponsor concluded the event was unlikely directly related but discontinued the program nonetheless [5]. Long-term human safety data on CJC-1295 is absent.
Safety profile in published research
Short-term safety in the two published Phase 1 studies (Teichman 2006, Ionescu 2006) was reported as acceptable at the tested doses, with the standard short-term adverse-effect profile described above and no serious adverse reactions [3][4]. Long-term safety is undefined — no completed Phase 2 or Phase 3 trial has produced multi-month or multi-year safety data in humans. The 2006 Phase 2 trial that would have produced that record was terminated [5][9].
Regulatory status reflects this gap. CJC-1295 is not approved by the FDA, the EMA, or any other regulator for any therapeutic indication [16]. It is classed as an Investigational New Drug in the United States. The FDA removed CJC-1295 and ipamorelin acetate from Section 503A Category 2 (bulk drug substances under evaluation for compounding) effective 27 September 2024, leaving both compounds in regulatory limbo — not Category 1 (permitted) and no longer Category 2 (under evaluation) [16]. The World Anti-Doping Agency prohibits CJC-1295 under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics), in and out of competition [7].
Stacked side-effect profile with ipamorelin
The CJC-1295 + ipamorelin paired protocol carries the side-effect profile of CJC-1295 alone plus the ipamorelin-specific profile [12]. Ipamorelin's distinguishing pharmacological feature is selectivity — it releases GH without significantly elevating ACTH, cortisol, or prolactin even at high doses [12]. Reported short-term effects added by ipamorelin in the observational research literature include transient hunger (consistent with its ghrelin-receptor agonism), occasional mild GI symptoms, and the standard injection-site reactions [12].
No completed Phase 2 or Phase 3 trial has formally evaluated the paired CJC-1295 + ipamorelin protocol in humans against placebo control. The paired safety record is observational and preclinical. Long-term safety of the paired protocol is undefined.
Combinations cautioned against in the literature
Published clinical reviews caution against specific combinations involving CJC-1295. Stacking multiple GHRH analogs — for example CJC-1295-DAC together with sermorelin or tesamorelin — amplifies GH/IGF-1 elevation and is cautioned against on additive insulin-resistance and proliferative-risk grounds [15]. Pairing CJC-1295 with exogenous insulin or anabolic agents in the same protocol is similarly flagged, on the same grounds [15].
The principle the literature supports is conservative receptor-pathway-counting: one mechanism of GH-axis stimulation at a time, with the GH-axis biomarkers (GH, IGF-1) monitored; chronic stacking of multiple GH-stimulation pathways without monitoring is cautioned against [15].